Discontinuation of medication due to adverse events · people with chronic hepatitis C
Peginterferon plus ribavirin showed no clear difference in adverse events leading to treatment discontinuation compared with non‐pegylated interferon plus ribavirin (low certainty).
1 finding from 1 review
Sustained virological response · people with chronic hepatitis C
It is very uncertain whether peginterferon plus ribavirin changes sustained virological response compared with non‐pegylated interferon plus ribavirin (very low certainty).
1 finding from 1 review
All‐cause mortality Deaths during and after the treatment · people with chronic hepatitis C
It is very uncertain whether peginterferon alpha‐2a changes all‐cause mortality Deaths during and after the treatment compared with peginterferon alpha‐2b (very low certainty).
1 finding from 1 review
Liver morbidity · people with chronic hepatitis C
It is very uncertain whether peginterferon alpha‐2a changes liver‐related morbidity Number of events compared with peginterferon alpha‐2b (very low certainty).
1 finding from 1 review
Serious adverse events Number of events · people with chronic hepatitis C
Peginterferon alpha‐2a showed no clear difference in serious adverse events Number of events compared with peginterferon alpha‐2b (low certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events · people with chronic hepatitis C
Peginterferon alpha‐2a showed no clear difference in adverse events leading to treatment discontinuation Number of events compared with peginterferon alpha‐2b (low certainty).
1 finding from 1 review
All other (non‐serious) adverse events · people with chronic hepatitis C
1 finding from 1 review
Quality of life SF 36 and CLDQ · people with chronic hepatitis C
1 finding from 1 review
Sustained virological response · people with chronic hepatitis C
Peginterferon alpha‐2a probably leads to higher sustained virological response Absence of viraemia 24 weeks after… compared with peginterferon alpha‐2b (moderate certainty).
1 finding from 1 review
Selective bowel decontamination versus inactive control · people undergoing liver transplantation
It is very uncertain whether intervention changes selective bowel decontamination versus inactive control compared with control (very low certainty).
2 findings from 1 review
Granulocyte‐colony stimulating factor (G‐CSF) versus placebo · people undergoing liver transplantation
It is very uncertain whether intervention changes granulocyte‐colony stimulating factor (G‐CSF) versus placebo compared with control (very low certainty).
2 findings from 1 review
Selective bowel decontamination versus prebiotics with probiotics · people undergoing liver transplantation
2 findings from 1 review
Selective bowel decontamination versus prebiotics · people undergoing liver transplantation
2 findings from 1 review
Prebiotics with probiotics versus prebiotics · people undergoing liver transplantation
2 findings from 1 review
All‐cause mortality · patients with laparoscopic cholecystectomy.
1 finding from 1 review
Serious adverse events · patients with laparoscopic cholecystectomy.
It is very uncertain whether low pressure changes serious adverse events compared with standard pressure pneumoperitoneum (very low certainty).
1 finding from 1 review
Conversion to open cholecystectomy · patients with laparoscopic cholecystectomy.
It is very uncertain whether low pressure changes conversion to open cholecystectomy compared with standard pressure pneumoperitoneum (very low certainty).
1 finding from 1 review
Length of hospital stay · patients with laparoscopic cholecystectomy.
1 finding from 1 review
Operating time · patients with laparoscopic cholecystectomy.
1 finding from 1 review
All‐cause mortality · patients with people undergoing laparoscopic cholecystectomy.
1 finding from 1 review